MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, WGSWW had $19,787K increase in cash & cash equivalents over the period. $14,262K in free cash flow.

Cash Flow Overview

Change in Cash
$19,787K
Free Cash flow
$14,262K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from offerings, net of ...
    • Proceeds from maturities of mark...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Accounts receivable
    • Acquisition of business, net of ...
    • Others

Cash Flow
2025-12-31
Net loss
-21,021
Depreciation and amortization expense
25,224
Stock-based compensation expense
32,162
Change in fair value of financial liabilities
1,204
Provision for excess and obsolete inventory
135
Legal reserves
-5,560
Change in third party payor reserves
-2,449
Impairment loss
0
Other
3,163
Accounts receivable
36,231
Inventory
3,436
Accounts payable and accrued expenses
12,100
Other assets and liabilities
-11,970
Net cash provided by (used in) operating activities
33,279
Acquisition of business, net of cash acquired and consideration on escrow paid for legacy genedx acquisition-Series Of Individually Immaterial Business Acquisitions
32,856
Acquisition of business, net of cash acquired and consideration on escrow paid for legacy genedx acquisition-Gene Dx
0
Purchases of marketable securities
55,676
Proceeds from sales of marketable securities
2,062
Proceeds from maturities of marketable securities
43,970
Purchases of property and equipment
19,017
Proceeds from sales of assets
0
Development of internal-use software assets
0
Net cash used in investing activities
-61,517
Proceeds from offerings, net of issuance costs
46,704
Proceeds from issuance of stock pursuant to employee stock purchase plan
2,961
Exercise of stock options
2,022
Long-term debt principal payments
1,211
Finance lease payoff and principal payments
2,451
Proceeds from long-term debt
0
Net cash provided by financing activities
48,025
Net increase (decrease) in cash, cash equivalents and restricted cash
19,787
Cash, cash equivalents and restricted cash, at beginning of year
86,202
Cash, cash equivalents and restricted cash, at end of year
105,989
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from offerings,net of issuance...$46,704K Proceeds from issuance ofstock pursuant to...$2,961K Stock-based compensationexpense$32,162K Depreciation andamortization expense$25,224K Exercise of stock options$2,022K Accounts payable andaccrued expenses$12,100K Other assets andliabilities-$11,970K Legal reserves-$5,560K Other$3,163K Change in third partypayor reserves-$2,449K Change in fair value offinancial liabilities$1,204K Provision for excess andobsolete inventory$135K Net cash provided byfinancing activities$48,025K Net cash provided by(used in) operating...$33,279K Canceled cashflow$3,662K Canceled cashflow$60,688K Net increase(decrease) in cash, cash...$19,787K Canceled cashflow$61,517K Finance lease payoff andprincipal payments$2,451K Long-term debt principalpayments$1,211K Proceeds from maturitiesof marketable...$43,970K Proceeds from sales ofmarketable securities$2,062K Accounts receivable$36,231K Net loss-$21,021K Inventory$3,436K Net cash used ininvesting activities-$61,517K Canceled cashflow$46,032K Purchases of marketablesecurities$55,676K Acquisition of business, netof cash acquired...$32,856K Purchases of property andequipment$19,017K

GeneDx Holdings Corp. (WGSWW)

GeneDx Holdings Corp. (WGSWW)